Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
CG Oncology, Inc. (CGON) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $69.16, with a market capitalisation of $6.54B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $34.51 to $80.97. This page covers its latest market performance, valuation, price trends and company information.
$6.54B | |
$72.55 | |
$80.97 | |
$14.80 | |
$72.55 | |
1.94K | |
938.83K | |
-- | |
$80.97 | |
$34.51 | |
-- | |
-- |
CG Oncology, Inc. (CGON) is trading at $68.49 in pre-market trading as of 2026-09-16 13:19:00, down 5.60% ($4.06) from the previous close of $72.55
Pre-market trading shows how investors are pricing CGON before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, CG Oncology, Inc. (CGON) moved from $74.67 to $69.16, representing a decline of 7.37% ($5.51).
The stock traded between $68.49 and $75.00 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 689.47 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 74.6%
CGON is currently trading at $69.16, placing it 74.6% of the way from its 52-week low of $34.51 to its 52-week high of $80.97. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 142 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CG Oncology, Inc. (CGON) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.